With accelerated development in the field of early screening, the companies products, industry development, in the direction of the mature specification in education at the same time, focus on clinical research and market in the future how to solve the problem of multi-channel, pay problem, make cancer early screening, really meet the needs of clinical pain points and patients become cancer early sieve enterprise need to think about and layout problem.
“Partnering can bring 1+1.
All parties can make full use of their strengths to provide comprehensive services of ‘platform, technology, medical care and security’ for patients and their families, “Zhou Jun, CEO of Herui Genomics, told Caijing.
In the past year, Herui Genomics has been exploring cooperation with insurance, Internet companies, tumor imaging companies and many other role enterprises.
“This collaboration and ali health, is based on our people to disease classification and positioning for early screening target population, first of all on liver cancer early screening products out of the first step, but will also continue to cooperation, will explore more likely, from medicines to insurance, even based on ali health data for clinical exploration and development technology, and more cooperation in the future.”
“Only by forming a closed loop can we call it a complete early screening program.”
Announced a few days ago, ali health officially launched “slow disease protection scheme”, introduced millions of health care service “hepatitis b protect”, according to ali’s health, according to demand of hepatitis b patients with buy medicine and protection, can choose many hepatitis b daily medicine, if the insured person to cirrhosis of the liver, unfortunately by the applicant for liver cancer early screening, even after the diagnosis of liver cancer,
The insured will also receive expert consultation services provided by Ali Health and reimbursement of medical expenses for liver cancer provided by Zhongan Insurance.
The whole project in the middle of the ring is in a high-risk population screening for link, this part of the crowd in turn cancer risk compared with the general significantly increased in patients with liver disease, “this and our people to disease classification and early screening the positioning of the target population is the same, we need to identify high-risk in slow disease, extremely high risk people”,
In this project, by providing the early screening product of liver cancer, Lathning, HerueGenomics set up an online and offline integrated health service mode, providing solutions including prevention, screening, treatment and rehabilitation for people at high risk of liver cancer. Together, HerueGenomics has opened a closed loop of “medical treatment + medicine + testing + insurance”.
“This collaboration is the first step based on HCC early screening products, but the collaboration will continue, and more possibilities will be explored, ranging from drugs to insurance, and even clinical exploration and development based on Ali Health data technology, as well as cooperation on more products in the future,” Zhou told Caijing.
In the field of early screening and diagnosis of tumors, Herugenomics has launched a series of clinical research projects on early screening and early diagnosis of tumors, including liver cancer, lung cancer and other high-risk tumors in China. The clinical grade liver cancer early screening product Lesning has been launched in August 2020.
With the launch of products and the rapid development of the industry, while focusing on clinical research and market education, cancer early screening companies need to think and layout about how to solve the problem of multi-channel and multi-payment in the future, so that cancer early screening enterprises can truly realize the implementation of clinical pain points and patients’ needs.
In this project, the two sides will provide users with multi-level health security system and compensation system, “lai si ning” as part of an insurance premium services, and in the past few months, and gene is active cooperation and more insurance companies to explore, in March 2021, and genes and taikang online, anhua agricultural insurance also reached a cooperation, respectively.
“Medical insurance is the ideal, while commercial insurance is the reality,” said Zhou Jun frankly. Public hospitals in China are the dominant ones, and patients in hospitals are one of the main business models for early screening products. Cancer early screening still needs to be paid by oneself.
The second is to adapt to the clinical environment in China. What are the needs of the patients? The examination alone cannot solve the problem of payment or diagnosis and treatment, so it cannot be called a complete early screening program.”
In his view, building a Chinese program for early cancer screening and prevention requires the integration of all aspects, from commercial to clinical, from technology to industry.
“In the future, the company will continue to deepen the depth and breadth of cooperation with partners, expand the layout of cancer early screening product line, inject new momentum into the research and development of high incidence and high-risk cancer early screening in China, and work with ecological partners to realize the mission of ‘early diagnosis and early treatment for all tumors’.”
“Clinical grade early screening products depend on the data”
According to ali, health, vice President, noting, “based on the health of the whole scene ali medical service capacity, and high specificity of genome and gene detection technology and large sample clinical research, the further cooperation is the comprehensive exploration on the disease care, and will use science and technology innovation, around more diseases to design a new model of health management.”
Zhou Jun also revealed that Ali Health had done a lot of “back research” before choosing Hexigen, and had made an understanding of the technical path and clinical data of the product.
A clinical-grade early screening product still depends on the data.
In 2020, Hereogen announced the roadmap for early screening and early diagnosis of multiple tumor species:
Within three to five years, Herui Genomics will deliver research results on early screening and early diagnosis of 5 to 8 types of high-risk and high-incidence tumors in China, and carry out industrial implementation. Lesning will be launched in August 2020 for the screening of liver cancer in high-risk groups, which is 6-12 months earlier than the traditional method for the early warning of liver cancer.
The related achievements of HIFI technology have also been published in the international authoritative journal Cell Research (IF=20.5), which has been recognized by international authorities.
On June 22, the Chinese Journal of Liver Diseases officially published the first expert consensus on early screening strategies for liver cancer in China, which was led by the national multi-center prospective screening program for extremely early warning of liver cancer (PRECAR).
Herui gene cfDNA whole genome sequencing technology for early screening of liver cancer is incorporated into the “pyramid” model for early screening of liver cancer. Through the model of preliminary screening, fine screening and early diagnosis, the risk groups are enriched and concentrated layer by layer, and the detection efficiency of early liver cancer is finally improved.
The Consensus showed that the HIFI scoring model based on cfDNA whole genome sequencing had a stable performance, with a sensitivity of 95.42% and specificity of 97.91% to distinguish between HCC and non-HCC.
“A product can’t solve a clinical problem and will eventually degenerate into a consumer product,” Zhou Jun told Caijing.com. “China’s clinical environment is centered on clinicians, and doctors’ opinions and opinions are very important to the implementation of early screening products in the whole society.
At the same time, the approval of clinicians is not only an endorsement, we want to provide early screening program, the other end of the cancer diagnosis and treatment loop occurs in the clinic, the screening results must be accepted by the clinic, the clinical program can be adjusted accordingly, if the clinic is not recognized, this value will be greatly reduced.
Based on these two factors, we think it’s time to put resources into the clinic.”
In April of this year, the Precar program announced new progress and will launch the Ⅱ phase III clinical application extensibility study, which extends from early screening to the management of the entire course of HCC.
Why the Ⅱ phase III trial?
“One is to give people a better understanding of the performance and clinical use of our products, and the other is to help doctors deepen their understanding of clinical testing,” said Zhou Jun.
About how to understand to the whole course of the management of liver cancer, he explains the financial network, “the first is about some malignant nodules, because now we say that the liver is above there are a lot of nodules, cirrhosis of the liver itself has nodules, how to determine the clinical doctors are interested in, which is originated in the us with clinical doctors to do some tests, and see if I can do the judgement of nodules.
The clinician also mentioned that since early screening can be done to detect recurrence, “the underlying technology is similar, we will make some adjustments, and we will judge whether it can adapt to the actual clinical results, and finally illustrate with data.”